Payment overview · 2025
General Payments
$312.85
15 reported records · 4 companies
Healthcare provider profile · identity verified
Aaron Newcomb, DO
Allopathic & Osteopathic Physicians|Family Medicine · CARBONDALE, IL · NPI 1568636470
Verified facts
What the public records show
CMS Open Payments records show Aaron Newcomb, DO received $312.85 in general payments during 2025 across 15 reported records.
Indivior Inc. accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $130.99 | 41.9% | 6 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $119.79 | 38.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.79 | 10.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.28 | 9.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.85 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $130.99 | 6 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $119.79 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.28 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 566 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 98 |
| Gabapentin | Gabapentin | 333 | 56 |
| Lisinopril | Lisinopril | 303 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 82 |
| Clonazepam | Clonazepam | 278 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 60 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 242 | 25 |
| Buprenorphine Hcl | Buprenorphine Hcl | 241 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 59 |
| Omeprazole | Omeprazole | 201 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 194 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 187 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 44 |
| Losartan Potassium | Losartan Potassium | 171 | 36 |
| Spironolactone | Spironolactone | 161 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 27 |
| Eliquis | Apixaban | 151 | 19 |
| Prednisone | Prednisone | 145 | 72 |
| Furosemide | Furosemide | 144 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 25 |
| Famotidine | Famotidine | 139 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 32 |
| Pregabalin | Pregabalin | 126 | 25 |
| Trazodone Hcl | Trazodone Hcl | 126 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 29 |
| Diazepam | Diazepam | 114 | 19 |
| Ozempic | Semaglutide | 110 | 16 |
| Lorazepam | Lorazepam | 107 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 23 |
| Metformin Hcl | Metformin Hcl | 92 | 22 |
| Jardiance | Empagliflozin | 86 | 23 |
| Baclofen | Baclofen | 85 | 20 |
| Montelukast Sodium | Montelukast Sodium | 85 | 21 |
| Potassium Chloride | Potassium Chloride | 84 | 26 |
| Carvedilol | Carvedilol | 79 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 20 |
| Ibuprofen | Ibuprofen | 68 | 19 |
| Buspirone Hcl | Buspirone Hcl | 66 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 13 |
| Nifedipine Er | Nifedipine | 61 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 12 |
| Tramadol Hcl | Tramadol Hcl | 58 | 14 |
| Azithromycin | Azithromycin | 56 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 24 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 52 | suppressed |
| Methadone Hcl | Methadone Hcl | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 12 |
| Finasteride | Finasteride | 50 | 14 |
| Olanzapine | Olanzapine | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 43 | 38 |
| Alendronate Sodium | Alendronate Sodium | 42 | 17 |
| Aripiprazole | Aripiprazole | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 24 |
| Celecoxib | Celecoxib | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Lurasidone Hcl | Lurasidone Hcl | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Nystatin | Nystatin | 29 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 15 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Haloperidol Decanoate | Haloperidol Decanoate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 12 |
| Testosterone | Testosterone | 23 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Buprenorphine | Buprenorphine | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.85 · 15 records | Indivior Inc. | AREXVY, BEXSERO, BRIXADI, PENMENVY, SHINGRIX, SUBLOCADE, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error